Geron competitors

Geron Competitors include Aptevo Therapeutics, Cleveland BioLabs, Heat Biologics and Immune Design.
Add company...
Geron
Geron
Geron is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Aptevo Therapeutics
Aptevo Therapeutics
Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market.
Cleveland BioLabs
Cleveland BioLabs
CBLI’s mission is to develop and commercialize innovative drugs to treat cancer and protect healthy tissues from radiation, chemotherapy or ischemic conditions.
Heat Biologics
Heat Biologics
Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic “off-the-shelf” cell based immunotherapy to treat patients with a wide array of cancers and infectious diseases.
Immune Design
Immune Design
Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases.
Founding Date
Founding Date
1990
Founding Date
2016
Founding Date
2003
Founding Date
2008
Founding Date
2008
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Menlo Park, US HQ
Canton, US
Locations
Seattle, US HQ
Locations
Buffalo, US HQ
Locations
Durham, US HQ
Locations
Seattle, US HQ
South San Francisco, US
Employees
Employees
15
Employees
1213% increase
Employees
1220% decrease
Employees
19
Employees
5510% increase
Valuation ($)
Valuation ($)
279.5 m
Valuation ($)
54.7 m
Valuation ($)
22.4 m
Valuation ($)
45.4 m
Valuation ($)
84.8 m

Financial

Revenue (est.)
Revenue (est.)
$1.1m (FY, 2017)
Revenue (est.)
$14.7m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$7.2m (FY, 2017)
Cost of goods
Cost of goods
N/A
Cost of goods
$5m (FY, 2017)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$84k (FY, 2017)
Gross profit
Gross profit
N/A
Gross profit
$9.6m (FY, 2017)
Gross profit
N/A
Gross profit
N/A
Gross profit
$7.1m (FY, 2017)
Net income
Net income
($27.9m) (FY, 2017)
Net income
$7m (FY, 2017)
Net income
($9.8m) (FY, 2017)
Net income
($12.4m) (FY, 2017)
Net income
($51.9m) (FY, 2017)

Funding

Total funding raised
Total funding raised
$ 96.7m
Total funding raised
N/A
Total funding raised
$ 12.2m
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

Aptevo Therapeutics
HQ
Seattle, US
Employees
121↑ 3% increase

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market.

View company
Cleveland BioLabs
HQ
Buffalo, US
Employees
12↓ 20% decrease

CBLI’s mission is to develop and commercialize innovative drugs to treat cancer and protect healthy tissues from radiation, chemotherapy or ischemic conditions.

View company
Heat Biologics
HQ
Durham, US
Employees
19

Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic “off-the-shelf” cell based immunotherapy to treat patients with a wide array of cancers and infectious diseases.

View company
Immune Design
HQ
Seattle, US
Employees
55↑ 10% increase

Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases.

View company